Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Classical hematology 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Flow Cytometry 36Gene Expression Profiling 34Surveys and Questionnaires 27Polymerase Chain Reaction 24Microarray Analysis 23Blood Specimen Collection 19Interviews as Topic 18Imatinib Mesylate 15Amplified Fragment Length Polymorphism Analysis 14Reverse Transcriptase Polymerase Chain Reaction 13Cytogenetic Analysis 13Rituximab 12venetoclax 11nilotinib 10Psychiatric Rehabilitation 10Dasatinib 10Immunologic Techniques 9DNA Methylation 9Blotting, Western 9ponatinib 8Watchful Waiting 8Observation 8In Situ Hybridization, Fluorescence 8Base Sequence 8Azacitidine 8ibrutinib 7fludarabine 7bosutinib 7Therapeutics 7Specimen Handling 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Piperacillin, Tazobactam Drug Combination × Other hematologic neoplasm × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡